# ACTIN Report (research use only)

PATIENT
EXAMPLE-LUNG-01

REPORT DATE
31-Oct-2024

Gender: Male | Birth year: 1950 | WHO: 0

Tumor: Lung - Adenocarcinoma | Lesions: Liver | Stage: IV

## Summary

### Clinical summary

| | | |
|---|---|---|
| Relevant systemic treatment history | **1/2023-9/2024** | **Osimertinib** |
| Relevant other oncological history | **None** | |
| Previous primary tumor | **None** | |
| Relevant non-oncological history | **2022** | **Rheumatoid arthritis** |

### Recent molecular results

| | |
|---|---|
| Hartwig WGS results | **No successful WGS could be performed on the submitted biopsy** |
| **IHC results** | **PD-L1: Score 1%** |

### Example trials that are open and potentially eligible (0)

None

### Example trials that are open and potentially eligible but currently have no slots available (1 cohort from 1 trial)

| Trial | Cohort | Molecular | Warnings |
|---|---|---|---|
| **METC 01** IEMOEN | Dose escalation - monotherapy | | Hemoglobin 5.6 mmol/L below min of 6.0 mmol/L, History of rheumatoid arthritis, SOC not exhausted: at least platinum doublet remaining |

### Example trials that are open but for which additional genes need to be tested to evaluate eligibility (3 cohorts from 3 trials)

| Trial | Cohort | Molecular | Warnings |
|---|---|---|---|
| **METC 02** KAYRAS | Dose expansion - monotherapy - NSCLC | | No molecular data with sufficient quality |
| **METC 03** NO-SEE797ES | Dose escalation - monotherapy | | No molecular data with sufficient quality |
| **METC 04** TEDR1 | Lung cancer C797S cohort | | No molecular data with sufficient quality |

Open cohorts with no slots available are shown in grey.

## Trial Matching Summary

### Example trials and cohorts that may be eligible, but are closed (1)

| Trial | Cohort | Molecular | Warnings |
|---|---|---|---|
| **METC 01**<br>IEMOEN | Dose expansion - monotherapy | | Hemoglobin 5.6 mmol/L below min of 6.0 mmol/L, History of rheumatoid arthritis, SOC not exhausted: at least platinum doublet remaining |

### Example trials and cohorts that are considered ineligible (1)

| Trial | Cohort | Molecular | Ineligibility reasons |
|---|---|---|---|
| **METC 02**<br>KAYRAS | Dose expansion - monotherapy - Colorectum | | No colorectal cancer |

Open cohorts with no slots available are shown in grey.

## Trial Matching Details

### Potentially eligible open trials & cohorts

#### METC 01

| | |
|---|---|
| Potentially eligible | **Yes** |
| Acronym | **IEMOEN** |
| Title | **Phase I first-in-human study to evaluate safety of IEMOEN, a new PD-L1 inhibitor in advanced solid tumors** |

| Rule | Reference | Evaluation |
|---|---|---|
| E-02 | Has hemoglobin below 6 mmol/l | FAIL (potentially recoverable)<br>Hemoglobin 5.6 mmol/L is below minimum of 6.0 mmol/L |
| I-03 | Patient should have exhausted applicable available standard-of-care treatments. | WARN<br>Patient has not exhausted SOC (at least platinum doublet remaining) |
| E-01 | Has an active autoimmune disease that requires systemic treatment and poses a risk according to the investigator. | WARN<br>Patient has history of condition(s) rheumatoid arthritis, which is indicative of autoimmune disease |
| E-03 | Has absolute neutrophil count below 1.5 x 10^9/l | UNDETERMINED<br>No measurement found for absolute neutrophil count |
| I-01 | Patients must be ≥18 years old. | PASS<br>Patient is at least 18 years old |
| I-02 | IEMOEN monotherapy is indicated for the treatment of adults with advanced/metastatic solid tumors. | PASS<br>Patient has solid primary tumor<br>Tumor stage IV is considered metastatic |

#### METC 01 - Dose escalation - monotherapy

| | |
|---|---|
| Cohort ID | **A** |
| Potentially eligible? | **Yes** |
| Open for inclusion? | **Yes** |
| Has slots available? | **No** |

#### METC 01 - Dose expansion - monotherapy

| | |
|---|---|
| Cohort ID | **B** |
| Potentially eligible? | **Yes** |
| Open for inclusion? | **No** |
| Has slots available? | **No** |

## METC 02

| | |
|---|---|
| Potentially eligible | **Yes** |
| Acronym | **KAYRAS** |
| Title | **A phase 1/2 trial for first in-human usage of KAYRAS, a new specific KRAS G12D inhibitor in NSCLC and colorectal cancer** |

| Rule | Reference | Evaluation |
|---|---|---|
| I-03 | ALAT and ASAT should be at most 3*ULN, or at most 5*ULN in case of liver metastases. | UNDETERMINED<br>ASAT and ALAT are not present or cannot be evaluated |
| I-04 | Patient has confirmed KRAS G12D mutation | UNDETERMINED<br>No molecular data with sufficient quality |
| I-01 | Patient is ≥18 years old. | PASS<br>Patient is at least 18 years old |
| I-02 | KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer. | PASS<br>Tumor stage IV is considered metastatic |

## METC 02 - Dose expansion - monotherapy - NSCLC

| | |
|---|---|
| Cohort ID | **A** |
| Potentially eligible? | **Yes** |
| Open for inclusion? | **Yes** |
| Has slots available? | **Yes** |

| Rule | Reference | Evaluation |
|---|---|---|
| I-02 | KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer. | PASS<br>Patient has tumor belonging to DOID term(s) lung non-small cell carcinoma |

## METC 02 - Dose expansion - monotherapy - Colorectum

| | |
|---|---|
| Cohort ID | **B** |
| Potentially eligible? | **No** |
| Open for inclusion? | **Yes** |
| Has slots available? | **Yes** |

| Rule | Reference | Evaluation |
|---|---|---|
| I-02 | KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer. | FAIL<br>Patient has no colorectal cancer |

## METC 03

| | |
|---|---|
| Potentially eligible | **Yes** |
| Acronym | **NO-SEE797ES** |
| Title | **Phase I trial for development of NO-SEE797ES, a specific inhibitor for EGFR with C797 mutations but not C797S in solid tumors** |

| Rule | Reference | Evaluation |
|---|---|---|
| I-03 | Tumors should contain EGFR C797 but not EGFR C797S mutation. | UNDETERMINED<br>No molecular data with sufficient quality |
| I-01 | Patient is ≥18 years of age. | PASS<br>Patient is at least 18 years old |
| I-02 | Monotherapy is indicated for the treatment of adults with advanced/metastatic solid tumors. | PASS<br>Tumor stage IV is considered metastatic |

## METC 03 - Dose escalation - monotherapy

| | |
|---|---|
| Cohort ID | **A** |
| Potentially eligible? | **Yes** |
| Open for inclusion? | **Yes** |
| Has slots available? | **Yes** |

## METC 04

| | |
|---|---|
| Potentially eligible | **Yes** |
| Acronym | **TEDR1** |
| Title | **TEDR1 Trial: A phase II trial to evaluate efficacy of specific EGFR inhibitors in lung cancer** |

| Rule | Reference | Evaluation |
|---|---|---|
| I-3 | Patient has a confirmed EGFR C797S mutation | UNDETERMINED<br>No molecular data with sufficient quality |
| I-1 | Patient is ≥18 years of age. | PASS<br>Patient is at least 18 years old |
| I-2 | Drug 1 as monotherapy is indicated for the treatment of adults with advanced lung cancer. | PASS<br>Patient has tumor belonging to DOID term(s) lung cancer<br>Tumor stage IV is considered metastatic |

## METC 04 - Lung cancer C797S cohort

| | |
|---|---|
| Cohort ID | **A** |
| Potentially eligible? | **Yes** |
| Open for inclusion? | **Yes** |
| Has slots available? | **Yes** |